Published in J Affect Disord on February 02, 2012
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Rev Clin Pharmacol (2016) 0.75
Stress and depression. Annu Rev Clin Psychol (2005) 7.01
The effects of stressful life events on depression. Annu Rev Psychol (1997) 5.98
Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. Eur J Pharmacol (2008) 4.82
Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry (1992) 2.70
Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol (2008) 2.00
Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry (2004) 1.39
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res (2001) 1.31
The stages of mania. A longitudinal analysis of the manic episode. Arch Gen Psychiatry (1973) 1.29
Minireview: Stress-related psychiatric disorders with low cortisol levels: a metabolic hypothesis. Endocrinology (2011) 1.28
Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am (2005) 1.21
A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol (2010) 1.18
Signs and symptoms of mania in pure and mixed episodes. J Affect Disord (1998) 1.10
The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res (1999) 1.03
Incidence and signficiance of mixed affective states in a bipolar population. Arch Gen Psychiatry (1976) 1.02
Hypothalamic-pituitary-adrenal axis activity in depressive illness. Its relationship to classification. Arch Gen Psychiatry (1980) 1.00
The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry (1994) 0.97
Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry (1995) 0.96
A study of the relationship between serum lithium and plasma cortisol levels in manic depressive patients. Br J Clin Pharmacol (1979) 0.94
High levels of cortisol among adolescent offspring of parents with bipolar disorder: a pilot study. Psychoneuroendocrinology (2004) 0.92
Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res (1989) 0.89
Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry (1997) 0.87
The cortisol awakening response in bipolar illness: a pilot study. Can J Psychiatry (2003) 0.84
[Depression and stress: is there an endophenotype?]. Rev Bras Psiquiatr (2007) 0.83
Abnormal cortisol suppression in bipolar patients with simultaneous manic and depressive symptoms. Am J Psychiatry (1983) 0.83
Individual differences in plasma cortisol changes during mania and depression. J Affect Disord (1987) 0.82
Hypothalamic-pituitary-adrenocortical function in mixed and pure mania. Acta Psychiatr Scand (1992) 0.79
Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients. Psychol Med (1999) 0.79
The dexamethasone suppression test in acute mania. J Affect Disord (1984) 0.79
Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. Pharmacopsychiatry (2003) 0.78
Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients. Psychoneuroendocrinology (2007) 0.77
Increased CSF cortisol levels after neuroleptic treatment in schizophrenia. Psychoneuroendocrinology (1985) 0.77
The dexamethasone suppression test in mixed bipolar disorder. Am J Psychiatry (1983) 0.77
Depressive mania versus agitated depression: biogenic amine and hypothalamic-pituitary-adrenocortical function. Biol Psychiatry (1994) 0.77
Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. Arch Gen Psychiatry (1984) 0.77
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry (2014) 2.13
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.78
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev (2007) 1.36
Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett (2007) 1.35
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study. Biol Psychiatry (2008) 1.26
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. Int J Psychophysiol (2002) 1.17
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry (2005) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
The generators of slow potentials obtained during verbal, pictorial and spatial tasks. Int J Psychophysiol (2003) 1.16
Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci (2006) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Reduced cortical folding in schizophrenia: an MRI morphometric study. Am J Psychiatry (2003) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.08
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry (2009) 1.04
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.03
Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord (2007) 1.01
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry (2004) 1.00
Development and use of a biological rhythm interview. J Affect Disord (2009) 0.99
Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res (2003) 0.99
Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 0.98
Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett (2007) 0.98
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Neuroendocrine and immune contributors to fatigue. PM R (2010) 0.97
Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry (2010) 0.97
Mild cognitive impairment: cognitive screening or neuropsychological assessment? Rev Bras Psiquiatr (2008) 0.97
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) (2011) 0.96
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol Dis (2010) 0.94
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) (2014) 0.93
Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neuromolecular Med (2012) 0.93
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett (2011) 0.93
Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res (2012) 0.92
Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord (2009) 0.92
Early intervention in bipolar disorders: clinical, biochemical and neuroimaging imperatives. J Affect Disord (2008) 0.92
Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol (2008) 0.91
Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J Clin Psychiatry (2007) 0.90
Clinical impact of late diagnose of bipolar disorder. J Affect Disord (2005) 0.89
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull (2011) 0.89
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res (2010) 0.89
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets (2014) 0.89
Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr (2010) 0.88
Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res (2011) 0.88
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol (2007) 0.88
The immunology of bipolar disorder. Neuroimmunomodulation (2014) 0.87
Inflammatory aspects of depression. Inflamm Allergy Drug Targets (2008) 0.87
Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.87
Mild cognitive impairment. Part 1: clinical characteristics and predictors of dementia. Rev Bras Psiquiatr (2013) 0.87
Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol (2010) 0.86
Circulating Glial-derived neurotrophic factor is reduced in late-life depression. J Psychiatr Res (2011) 0.86
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res (2008) 0.86
Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids (2006) 0.86
Effects of the physical work environment on physiological measures of stress. Eur J Cardiovasc Prev Rehabil (2010) 0.86
Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology (Berl) (2008) 0.86
Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology (Berl) (2005) 0.85
Mismatch between self-reported quality of life and functional assessment in acute mania: a matter of unawareness of illness? J Affect Disord (2007) 0.85
Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett (2009) 0.85
A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry (2012) 0.85
Complex slow potential generators in a simplified attention paradigm. Int J Psychophysiol (2005) 0.84
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res (2004) 0.84
Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology (2012) 0.84
Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2007) 0.84
[A paradigm for understanding and treating psychiatric illness]. Rev Bras Psiquiatr (2007) 0.83
Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol (2013) 0.83
Association of the COMT Met¹⁵⁸ allele with trait impulsivity in healthy young adults. Mol Med Rep (2013) 0.83
Loss of interest, depressed mood and impact on the quality of life: cross-sectional survey. BMC Public Health (2011) 0.83
Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol Disord Drug Targets (2014) 0.83